Article Details
Retrieved on: 2024-07-11 17:27:37
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA approval of Alzheimer's drugs like donanemab and its efficacy and risks, notably with amyloid plaque-targeting treatments, amid historical and lifestyle factors. It aligns with "Lifestyle" by emphasizing non-drug, lifestyle modifications to potentially mitigate Alzheimer's progression and symptoms.
Article found on: medshadow.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here